Vaš brskalnik ne omogoča JavaScript!
JavaScript je nujen za pravilno delovanje teh spletnih strani. Omogočite JavaScript ali pa uporabite sodobnejši brskalnik.
Nacionalni portal odprte znanosti
Odprta znanost
DiKUL
slv
|
eng
Iskanje
Brskanje
Novo v RUL
Kaj je RUL
V številkah
Pomoč
Prijava
DPP-4 inhibitors in the prevention/treatment of pulmonary fibrosis, heart and kidney injury caused by covid-19-a therapeutic approach of choice in type 2 diabetic patients?
ID
Smelcerović, Andrija
(
Avtor
),
ID
Kocic, Gordana
(
Avtor
),
ID
Gajic, Mihajlo
(
Avtor
),
ID
Tomović, Katarina
(
Avtor
),
ID
Djordjevic, Vukica
(
Avtor
),
ID
Stankovic-Djordjevic, Dobrila
(
Avtor
),
ID
Anderluh, Marko
(
Avtor
)
PDF - Predstavitvena datoteka,
prenos
(375,34 KB)
MD5: 4E03EF535C418AF8D53F5B92F32A6D72
URL - Izvorni URL, za dostop obiščite
https://www.frontiersin.org/articles/10.3389/fphar.2020.01185/full
Galerija slik
Izvleček
Since the outbreak of SARS-CoV-2 virus more than 12,500,000 cases have been reported worldwide. Patients suffering from diabetes and other comorbidities are particularly susceptible to severe forms of the COVID-19, which might result in chronic complications following recovery. Dipeptidyl peptidase-4 inhibitors exert beneficial effects in prevention/treatment of pulmonary fibrosis, heart, and kidney injury, and since they may be a long-term consequence caused by COVID-19, it is reasonable to expect that DPP-4 inhibitors might be beneficial in alleviating long-term consequences of COVID-19. With that in mind, we would like to voice our concerns over chronic implications following recovery from COVID-19, especially not only in diabetic but also in non-diabetic patients, and to indicate that some preventive measures could be undertaken by application of DPP-4 inhibitors.
Jezik:
Angleški jezik
Ključne besede:
COVID-19
,
diabetes
,
DPP-4 inhibitors
,
fibrosis
,
multi-organ injury
Vrsta gradiva:
Članek v reviji
Tipologija:
1.01 - Izvirni znanstveni članek
Organizacija:
FFA - Fakulteta za farmacijo
Status publikacije:
Objavljeno
Različica publikacije:
Objavljena publikacija
Leto izida:
2020
Št. strani:
4 str.
Številčenje:
Vol. 11, art. 1185
PID:
20.500.12556/RUL-124557
UDK:
616.9+616.2
ISSN pri članku:
1663-9812
DOI:
10.3389/fphar.2020.01185
COBISS.SI-ID:
25125123
Datum objave v RUL:
02.02.2021
Število ogledov:
987
Število prenosov:
289
Metapodatki:
Citiraj gradivo
Navadno besedilo
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Kopiraj citat
Objavi na:
Gradivo je del revije
Naslov:
Frontiers in pharmacology
Skrajšan naslov:
Front Pharmacol
Založnik:
Frontiers Media
ISSN:
1663-9812
COBISS.SI-ID:
29551833
Licence
Licenca:
CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:
http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:
To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:
02.02.2021
Sekundarni jezik
Jezik:
Slovenski jezik
Ključne besede:
COVID-19
,
poškodbe notranjih organov
,
korona virus
,
DPP-4 zaviralci
,
pljučna fibroza
Projekti
Financer:
MESTD - Ministry of Education, Science and Technological Development of Republic of Serbia
Financer:
Drugi - Drug financer ali več financerjev
Program financ.:
Serbian Academy of Sciences and Arts, Niš
Številka projekta:
О-06-17
Financer:
Drugi - Drug financer ali več financerjev
Program financ.:
Faculty of Medicine of the University of Niš
Številka projekta:
internal project no. 40
Financer:
ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:
P1-0208
Naslov:
Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin
Podobna dela
Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:
Nazaj